Nephrocare to attend investor meet on June 2

0 min read Updated on 23 May 2026, 05:26 AM

Reviewed by

Suketu GScanX News Team

AI Summary

Nephrocare Health Services announced its participation in an investor conference on June 2, 2026, organized by Axis Capital in Mumbai. The meeting will involve group and one-on-one discussions based on publicly available information, with no UPSI to be shared.

*this image is generated using AI for illustrative purposes only.

Nephrocare Health Services has disclosed that its officials will participate in an investor conference scheduled for June 2, 2026. The intimation was made pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations.

The meeting is organized by Axis Capital and is set to take place in Mumbai. It will serve as a platform for group interactions as well as one-on-one meetings with analysts and institutional investors. The event is scheduled to commence at 11:00 A.M. IST onwards.

Date & Time	Event	Nature of Meeting	Place
June 02, 2026 11:00 A.M. IST Onwards	Axis Capital Conference	Group / 1*1 Meeting	Mumbai

The company clarified that the discussions during the conference will be strictly based on publicly available information. Nephrocare Health Services confirmed that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions. The schedule remains subject to changes due to exigencies on the part of the host or the company.

Historical Stock Returns for Nephrocare Health Services

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.10%	-5.69%	+13.79%	+28.83%	+28.83%	+28.83%

What strategic growth initiatives or expansion plans might Nephrocare Health Services highlight to attract institutional investor interest at the Axis Capital conference?

How could increased institutional investor visibility following this conference impact Nephrocare Health Services' stock liquidity and valuation multiples in the near term?

Are there any upcoming financial milestones, such as quarterly earnings or capacity expansions, that could make this investor conference particularly significant for Nephrocare Health Services?

Read Next Article

Nephrocare posts Q4 FY26 audio recording link

1 min read Updated on 21 May 2026, 01:58 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

Nephrocare Health Services has released the audio recording of its investors' conference call held on May 20, 2026, discussing the audited financial results for Q4 and FY26. The company reported a 32.2% increase in full-year revenue to ₹998.8 crore and a 22.1% rise in Q4 net profit to ₹30.4 crore, driven by volume growth and international expansion.

*this image is generated using AI for illustrative purposes only.

Nephrocare Health Services has released the audio recording of its investors' conference call regarding the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The conference call was held on May 20, 2026, and the recording is now available on the company's official website. This disclosure follows the company's announcement of its financial performance for the period, which highlighted significant growth in revenue and profitability.

Financial Performance Overview

The company reported a consolidated net profit of ₹30.4 crore for Q4 FY26, marking a year-on-year increase of 22.1%. For the full fiscal year, revenue grew significantly to ₹998.8 crore, an increase of 32.2% compared to ₹755.8 crore in FY25. The Adjusted PAT for the full year stood at ₹128.3 crore, reflecting a 74.6% increase from the previous year.

Key Financial Metrics

The following table summarises the key financial metrics for Q4 and FY26 on a year-on-year basis:

Metric	Q4 FY26	Q4 FY25	YoY	FY26	FY25	YoY
Revenue from Operations	₹265.6 crore	₹219.2 crore	21.2%	₹998.8 crore	₹755.8 crore	32.2%
Adj. EBITDA	₹55.4 crore	₹54.0 crore	2.6%	₹238.1 crore	₹173.0 crore	37.6%
Adj. EBITDA Margin	20.9%	24.6%	-380 bps	23.8%	22.9%	100 bps
Profit After Tax	₹30.4 crore	₹24.87 crore	22.1%	-	-	-

Operational and Strategic Highlights

Nephrocare Health Services recorded a notable rise in both revenue and net profit during Q4 FY26. Revenue growth was driven by a 15.2% increase in treatment volumes and a favorable mix shift towards international markets. The company noted that international revenue contribution rose from 31.8% in FY25 to 41.8% in FY26. The Return on Capital Employed (RoCE) for FY26 was reported at 22.8%, a growth of 290 basis points. The firm continues to leverage its asset-light model, with approximately 52% of clinics operating under a revenue-sharing arrangement.

Historical Stock Returns for Nephrocare Health Services

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.10%	-5.69%	+13.79%	+28.83%	+28.83%	+28.83%

With international revenue contribution surging from 31.8% to 41.8% in FY26, which specific geographies is Nephrocare targeting for further expansion, and what geopolitical or regulatory risks could threaten this growth trajectory?

Given the Q4 FY26 EBITDA margin compression of 380 basis points despite strong revenue growth, what cost pressures are emerging and can the company sustain its full-year margin improvement in FY27?

As Nephrocare approaches the ₹1,000 crore revenue milestone with its asset-light model, will the company consider transitioning to more owned clinic infrastructure to capture higher margins at scale?